Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $24.00.
Several research analysts have recently issued reports on TVTX shares. Guggenheim raised their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Bank of America raised their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Scotiabank upped their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald initiated coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating for the company. Finally, Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $9.00 to $27.00 in a research report on Monday, October 21st.
Check Out Our Latest Analysis on Travere Therapeutics
Insider Buying and Selling at Travere Therapeutics
Hedge Funds Weigh In On Travere Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of TVTX. R Squared Ltd acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $53,000. CWM LLC boosted its stake in Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares during the last quarter. Quarry LP purchased a new stake in Travere Therapeutics in the 3rd quarter valued at $105,000. Forefront Analytics LLC grew its holdings in Travere Therapeutics by 10.2% in the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after buying an additional 1,237 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Travere Therapeutics in the 2nd quarter worth $117,000.
Travere Therapeutics Stock Up 4.7 %
NASDAQ:TVTX opened at $21.07 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $21.56. The company has a market cap of $1.64 billion, a PE ratio of -4.63 and a beta of 0.70. The company’s 50 day moving average is $18.46 and its two-hundred day moving average is $15.10.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. During the same period in the previous year, the company earned ($1.17) earnings per share. The business’s quarterly revenue was up 69.6% compared to the same quarter last year. Analysts anticipate that Travere Therapeutics will post -3.92 EPS for the current year.
Travere Therapeutics Company Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Further Reading
- Five stocks we like better than Travere Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What Are the FAANG Stocks and Are They Good Investments?
- What Does the Future Hold for Eli Lilly?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.